PIQ (ASX) Ann: Study shows diabetes drug improves PromarkerD risk scores

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Hi Owl, Sincere thanks for taking the time to provide a very thorough response to my query. Your insight and knowledge of PIQ is of great benefit to many to less experienced investors in this area.

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

No.	Vol.	Price($)
2	101449	69.0¢

No.

Vol.

Price($)

101449

69.0¢

Price($)	Vol.	No.
71.0¢	10000	1

Price($)

Vol.

No.

71.0¢

10000

No.	Vol.	Price($)
2	101449	0.690
2	29779	0.685
4	19960	0.680
3	15406	0.675
4	30990	0.670

No.

Vol.

Price($)

101449

0.690

29779

0.685

19960

0.680

15406

0.675

30990

0.670

Price($)	Vol.	No.
0.710	10000	1
0.720	60000	1
0.730	158374	3
0.740	8000	1
0.750	29350	2

Price($)

Vol.

No.

0.710

10000

0.720

60000

0.730

158374

0.740

8000

0.750

29350

(20min delay)
Last 70.5¢		Change 0.010(1.44%)		Mkt cap ! $92.35M

Open	High	Low	Value	Volume
71.0¢	71.0¢	69.0¢	$10.51K	14.9K

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

HotCopper Highlights: Your most watched stocks for Week 46, 2024

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News